We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND-enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
This advanced, practice-oriented session explores how cyclodextrins enable safe, effective injectable formulations across small molecules and biologics, including protein therapeutics and vaccines.
The Masterclass blends scientific fundamentals, hands-on formulation strategy, and real-world case studies, addressing both opportunities and limitations while highlighting emerging directions in the field.
What You’ll Learn Parenteral-grade cyclodextrins: selection criteria, quality attributes, and regulatory expectations Formulation development & optimization: solubility enhancement, stability, compatibility, and excipient interactions Biologics-focused insights: protein stabilization, aggregation control, vaccine formulation considerations Small-molecule injectables: complexation strategies, safety margins, and performance trade-offs Case studies: successes, pitfalls, and decision frameworks from development to scale-up Limitations & risk management: toxicity thresholds, dosing constraints, and formulation boundaries What’s next: novel derivatives, new indications, and innovation pathways
Who Should Attend? This Masterclass is designed for professionals working in or transitioning to parenteral drug development, including:
Formulation Scientists & R&D Leaders (small molecules and biologics) CMC, Pharmaceutical Development & Technical Operations Teams Vaccine Developers & Protein Scientists Drug Delivery & Enabling Technology Specialists Regulatory Affairs & Quality Professionals Project Managers & Decision-Makers evaluating injectable formulation strategies
Why You’ll Benefit Practical, decision-ready knowledge: Move beyond theory to actionable formulation strategies Cross-modality perspective: Understand how cyclodextrins behave differently with proteins, vaccines, and small molecules Risk-aware development: Learn where cyclodextrins add value—and where they may not Accelerated development timelines: Apply proven approaches to reduce iteration cycles Future-proof insights: Stay ahead of regulatory, technological, and clinical trends
Format & Experience Live, expert-led online session Structured learning + applied examples Interactive discussion and Q&A Comprehensive takeaways you can apply immediately in development programs
Key Topics at a Glance Parenteral excipient requirements Cyclodextrin–API and cyclodextrin–protein interactions Stability, safety, and scalability Clinical and commercial considerations Innovation beyond current standards
Who It’s For (In One Line) If you develop, evaluate, or make decisions about injectable formulations—from early R&D to late-stage programs—this Masterclass is built for you.
This year’s journey of co-authoring multiple research papers (8), we feel proud and humbled by the collective effort and trust from our collaborators.
This effort has also been recognized when Milo Malanga PhD received the 1st Thorseinn Loftsson award for cyclodextrin research recently.
Our work — from advancing molecular understanding of cyclodextrin host–guest systems and enantioselective complexation, to proposing a clearer nomenclature for modified cyclodextrins, and exploring innovative drug delivery strategies — contributes to practical building blocks for pharmaceutical science.
Cyclodextrins and their derivatives remain versatile tools in enhancing drug solubility, stability, and delivery performance, and clearer frameworks and analytical insights help accelerate their adoption in real-world drug development.
Science is a shared effort — these studies represent many minds thinking together to address complex challenges in drug formulation and molecular design.
We are thankful to our co-authors, reviewers, and supporting institutions for making this possible.
Sequestering toxic 7-keto-cholesterol, our arch enemy from our bodies for good.
Our CSO, Milo Malanga PhD is among the inventors on this freshly published patent detailing this groundbreaking cyclodextrin dimer technology that has a chance to reverse atherosclerosis and change the life of hundreds of millions.
They propose a simple and fast synthetic strategy for preparing highly crystalline γ-cyclodextrin-based metal–organic frameworks (solid yield 100%). This is the first method that allows metal–organic frameworks with high surface areas to be synthesised without a washing step.
Today’s cyclodextrin is and Anti-Heparin Coagulant
Yes, you got it right.
From the development of Alveron Pharma, we already know it works.
This study reports an aminoethoxy-phenyl-pyridinium-modified γ-cyclodextrin (PyA-γ-CD) as a highly efficient coagulant for heparin through multivalent interactions.
PyA-γ-CD not only exhibits nearly complete neutralization activity for unfractionated heparin (UFH), but more importantly, it also effectively neutralizes three LMWHs (dalteparin (Dalte), enoxaparin (Enoxa), and nadroparin (Nadro)) with a broader therapeutic window compared to protamine.
Merck submitted supplemental new drug application which was received on June 12, 2024 by FDA for Bridion® (sugammadex) injection.
This request proposed to update Bridion Prescribing Information for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in pediatric patients from birth to less than 2 years of age.
Followed by Merck’s request, Bridion injection has been approved on December 12, 2024 for use in pediatric patients ages from birth to less than 2 years old for reversal of neuromuscular blockage induced by rocuronium bromide and vecuronium bromide.
The next chapter of the Bicyclos HEurope project brings a vivid and vibrant energy to Budapest.
Maria Antonietta Casulli and Catarina Fernandes from KU Leuven are spending a few months with us to make some cyclodextrin polymers suitable to incorporate into medical devices and also to shake up our lives.
Today’s cyclodextrin was a little gift under CarboHyde’s and GENEGUT’s Christmas tree.
This study identified the structural modifications that enhance gene delivery activity of a range of cationic amphiphilic CDs, including both β- and γ-CD.
Each CDs incorporated a C12 lipid chain on the primary face of the CD. On the secondary rim, at positions C2 and C3, either primary or tertiary amine groups.
A comparative in vitro study was conducted to assess the gene silencing efficacy of these nanoparticles using the luciferase reporter gene in A549-luc cells.
Gene silencing levels for both β- and γ-CDs increased when modified with a primary amine compared to a tertiary amine group at position C2. Gene expression inhibition was further improved when the CDs were functionalized with amine functionalities at positions C2 and C3.
Modification of the secondary side of γ-cyclodextrins with two sets of primary amine functionalities via a thiopropyl linker, as compared to a triazole linker, achieved up to 80% gene knockdown, regardless of dose.
